E
IRON icon

Ergoteles’s Disc Medicine IRON Stock Holding History

Ergoteles’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,402
Closed -$240K – 448
2023
Q2 		$240K Buy
+5,402
New +$192K 0.01% 825
2022
Q4 		– Sell
-3,073
Closed -$151K – 1666
2022
Q3 		$151K Sell
3,073
-464
-13% -$21.9K 0.01% 1273
2022
Q2 		$179K Buy
+3,537
New +$156K 0.01% 1369

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Ergoteles's IRON Position: Q3 2023 in Review

Ergoteles sold out of Disc Medicine (IRON) in Q3 2023, closing a stake of 5,402 shares — an estimated $240K sold.

Ergoteles first reported a position in IRON in Q2 2022 and held it in 3 quarters. The position peaked at $240K in Q2 2023. 91 funds tracked by Wall St. Rank hold IRON as of Q3 2023.

  • Ergoteles reported no remaining Disc Medicine position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 5,402 Disc Medicine shares in Q3 2023, an estimated $240K.
  • Ergoteles first reported a position in Disc Medicine in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Disc Medicine position peaked at $240K in Q2 2023.
  • 91 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.